SMi is delighted to announce its Highly Potent Active Pharmaceutical Ingredients conference coming to Boston on the 21st - 22nd October 2019.
The HPAPI global market is growing at an ever-increasing rate of CAGR at 8.6% that is projected to reach USD $31.56 Billion by 2025, with a significant segment market of HPAPI being oncology ADC which is at a CARG of a staggering 20%. The continual elevation of HPAPI potencies along with toxicity will further drive the needs for more cutting-edge containment solutions and best practices guidelines to ensure worker safety.
The event will explore how the latest technologies can benefit HPAPI with artificial intelligence and machine learning to hasten risk assessment and validation. We will also be dedicating much deserved attention on emerging HPAPI therapies including bispecific antibodies, oncolytic viral complexes and hormones. Will the super-high level 5 banding for these biologics prove effective or inept? Are current containment planning and solutions truly ensuing the health of workers? Come and find the answers to these hot topics of HPAPI along with the other unique insights such as continuous HPAPI manufacturing technologies.
Attend this conference and join our networking platform for industry professionals to provide you with the expertise to overcome the challenges of the HPAPI industry.